Nirogacestat

DB12005ApprovedInvestigationalSmall moleculeGamma Secretase Inhibitor

Nirogacestat is a gamma-secretase inhibitor used to treat desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling.

Chemical structure of Nirogacestat
Mechanism
Curator reviewed · 1 reference
Primary indication
Nirogacestat is indicated for adult patients with progressing desmoid tumors who require systemic treatment.Curator reviewed · 1 structured indication
Formula / weight
C27H41F2N5O · 489.656 g/mol (avg)
First approval
United States, 2023
Code names
PF-03084014 · PF- 3084014
Brand names
  • Ogsiveo

Resolves to

Compound
UNIIQZ62892OFJCAS1290543-63-3ChEMBLCHEMBL1770916ChEBI229217PubChem46224413
Clinical / RWD
RxNorm2670631ATCL01XX81
Structure
InChIKeyVFCRKLWBYMDAED-REWPJTCUSA-NSMILESCCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C
Targets
P49768PSEN1P49810PSEN2Q92542NCSTNQ9NZ42PSENENQ8WW43APH1BQ96BI3APH1A
Transporters
P08183ABCB1

What you can answer from here — as of September 23, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
910Drug interactionsStructured to mechanism, not free text
Sign in
25Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
3Marketed productsAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 26 drug categories
Sign in
25+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Nirogacestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In